| Citation: |
XUE Jing, XIAO Wenhuan, YAO Jing, ZHANG Jun. Effects of lurasidone on efficacy and cognitive function of patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 57-60. DOI: 10.7619/jcmp.20231119
|
To explore the clinical efficacy and safety of lurasidone in treating patients with schizophrenia and its influence on cognitive function.
A total of 80 patients with schizophrenia were selected and randomly divided into study group (treated with lurasidone) and control group (treated with quetiapine), with 40 cases in each group. After 12 weeks of treatment, the efficacy of the drugs was evaluated by the Positive and Negative Syndrome Scale (PANSS). The patient's neurocognitive function was evaluated by the Wisconsin Card Sorting Test (WCST) and the Paced Auditory Serial Addition Test (PASAT).
After treatment, there was no significant difference in the therapeutic effective rate between the two groups (P>0.05), but there were significant between-group differences in adverse reactions such as excessive sedation, drowsiness, abnormal electrocardiogram, abnormal liver function and weight gain (P < 0.05). The study group showed significant improvements in WCST total scores and perseverative errors before and after treatment, and the improvements in the study group were also significantly better than those in the control group after treatment.
Lurasidone and quetiapine have similar clinical efficacy in the treatment of schizophrenia, but lurasidone is able to achieve more significant improvement in cognitive impairments and adverse effects related to schizophrenia.
| [1] |
张晨熹, 刘登堂. 精神分裂症的神经心理学测评研究进展[J]. 神经疾病与精神卫生, 2022, 22(12): 899-903. https://www.cnki.com.cn/Article/CJFDTOTAL-JBJS202212011.htm
|
| [2] |
YUEN E Y, LI X N, WEI J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses[J]. Mol Pharmacol, 2012, 81(2): 113-119. doi: 10.1124/mol.111.076141
|
| [3] |
HORISAWA T, NISHIKAWA H, TOMA S, et al. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone[J]. Behav Brain Res, 2013, 244: 66-69. doi: 10.1016/j.bbr.2013.01.026
|
| [4] |
RAJAGOPAL L, MASSEY B W, MICHAEL E, et al. Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice[J]. Psychopharmacology, 2016, 233(4): 649-660. doi: 10.1007/s00213-015-4137-1
|
| [5] |
胡淼文, 朱浩, 魏宇梅, 等. 精神分裂症认知功能障碍的研究进展[J]. 神经疾病与精神卫生, 2021, 21(2): 128-133. https://www.cnki.com.cn/Article/CJFDTOTAL-JBJS202102010.htm
|
| [6] |
郑琪, 刘帮杉, 徐抒音, 等. 布南色林和鲁拉西酮改善精神分裂症患者认知功能的机制及临床应用研究进展[J]. 中南大学学报: 医学版, 2017, 42(4): 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD201704018.htm
|
| [7] |
GASBARRI A, POMPILI A. Serotonergic 5-HT7 receptors and cognition[J]. Rev Neurosci, 2014, 25(3): 311-323.
|
| [8] |
雷启佳, 郭文斌, 黄敏儿. 精神分裂症多巴胺D2族受体研究进展[J]. 中国临床康复, 2004, 8(36): 8345-8347. https://www.cnki.com.cn/Article/CJFDTOTAL-XDKF200436102.htm
|
| [9] |
杨翠, 赵颖, 胡小斐. 布南色林联合鲁拉西酮治疗精神分裂症的临床疗效及其对认知功能的影响[J]. 临床合理用药杂志, 2022, 15(36): 71-73. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202236021.htm
|
| [10] |
MURAI T, NAKAKO T, IKEDA K, et al. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone[J]. Behav Brain Res, 2014, 261: 26-30.
|
| [11] |
ICHIKAWA O, OKAZAKI K, NAKAHIRA H, et al. Structural insight into receptor-selectivity for lurasidone[J]. Neurochem Int, 2012, 61(7): 1133-1143.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: